Myelin basic protein in cerebrospinal fluid and other body fluids

Area of Science:

• Neuroscience
• Biochemistry
• Immunology

Background:

• Myelin basic protein (MBP) fragments can enter cerebrospinal fluid (CSF), serving as indicators of central nervous system (CNS) myelin damage.
• MBP detected immunochemically is termed MBP-like material (MBPLM), with its presence in CSF offering insights into CNS myelin injury.
• The dominant epitope of CSF MBPLM is located within the decapeptide 80-89 of the intact MBP molecule.

Purpose of the Study:

• To evaluate the clinical utility of detecting MBP-like material (MBPLM) in CSF for monitoring CNS myelin damage.
• To assess the role of CSF MBPLM as a marker for the presence, continuation, or resolution of CNS myelin injury.
• To explore the potential of MBPLM detection in body fluids for monitoring multiple sclerosis (MS) natural history and therapeutic response.

Main Methods:

• Immunochemical detection of MBP-like material (MBPLM) in cerebrospinal fluid (CSF).
• Analysis of CSF MBPLM levels in relation to acute relapse, chronic progression, and therapeutic interventions in MS.
• Investigation into the correlation of CSF MBPLM with disease activity and its distinction from other CSF markers.

Main Results:

• Normally, CSF contains no detectable MBPLM. Levels rise rapidly during acute MS relapses and decline thereafter.
• Elevated CSF MBPLM is associated with the mass and recency of CNS myelin damage, but is unusual in chronic MS phases.
• CSF MBPLM levels are independent of CSF protein, IgG, oligoclonal bands, and pleocytosis, and rarely elevated in optic neuritis.

Conclusions:

• CSF MBPLM serves as a valuable marker for documenting CNS myelin injury, particularly in acute phases of MS.
• CSF MBPLM has potential as a marker for therapeutic effectiveness in MS and predicts response to glucocorticoids.
• Developing assays for MBPLM in other body fluids, like urine, could enhance objective monitoring of MS progression and treatment outcomes.